New hope for rare eye disease: personalized drug schedule shows promise
NCT ID NCT05666804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a personalized treatment plan using the drug brolucizumab for people with a specific eye condition called polypoidal choroidal vasculopathy (PCV). The goal was to see if adjusting the treatment schedule based on each person's needs could maintain or improve vision while reducing how often they need injections. The study involved 148 adults aged 50 and older who had not been treated for this condition before, and it lasted 60 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Daegu, Dalseo Gu, 42602, South Korea
-
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
Daejeon, Korea, 35015, South Korea
-
Novartis Investigative Site
Seoul, Korea, 02447, South Korea
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Busan, 48108, South Korea
-
Novartis Investigative Site
Busan, 49241, South Korea
-
Novartis Investigative Site
Busan, 613-815, South Korea
-
Novartis Investigative Site
Daegu, 705703, South Korea
-
Novartis Investigative Site
Gwangju, 61469, South Korea
-
Novartis Investigative Site
Seoul, 01000, South Korea
-
Novartis Investigative Site
Seoul, 01869, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Seoul, 06273, South Korea